CLINICAL_TRIALS
trial_result
· 2023-10-18
Clinical Trial Update: A Study of IMR-687 in Subjects With Sickle Cell Disease [Phase 2]
Summary
Phase 2 study of IMR-687 in sickle cell disease has been terminated and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cardurion Pharmaceuticals, Inc. | Conditions: Sickle Cell Disease | Phase 2 | Status: TERMINATED | Results posted: 2023-10-18